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Evidence summary
A double-blind RCT comparing chasteberry 
tree with placebo in 170 patients found a de-
crease in self-reported PMS symptom scores 
and an increase in response rate (defi ned as 
a 50% reduction in symptoms)—52% vs 24%—
in the intervention group (number needed to 
treat [NNT]=3.5). Patients taking chasteberry 
tree had 1 occurrence of multiple abscesses 
and 1 of urticaria.1
A prospective, open-label study of chaste-
berry tree for PMS symptoms in 43 patients 
found a 42% decrease in self-assessed PMS 
symptom scores, with the greatest improve-
ment in pain, behavior changes, negative feel-
ings, and fl uid retention. No serious adverse 
events occurred.2
A third study comparing chasteberry 
tree with fl uoxetine in 19 patients found a 
decrease in premenstrual symptom scores 
for both fl uoxetine (13 of 19 patients) and 
chasteberry tree (11 of 19 patients). No 
statistically signifi cant 
diff erences were noted 
between the 2 groups. 
Chasteberry tree was well 
tolerated; most adverse ef-
fects occurred in patients 
receiving fl uoxetine. Th e 
most frequent adverse ef-
fects with chasteberry tree 
were nausea in 5 patients 
and headache in 4.3
Symptoms decrease 
signiﬁ cantly after 3 
calcium treatment cycles
Two RCTs (33 and 466 
patients) comparing 1000 and 1200 mg of 
calcium with placebo found a signifi cant de-
crease in PMS symptoms after 3 treatment 
cycles.4,5 Calcium improved negative aff ect, 
water retention, food cravings, and pain. In 
the fi rst study, 73% of patients preferred tak-
ing calcium, compared with 15% who pre-
ferred placebo.
Th e second study found that, by the third 
treatment cycle, patients taking calcium had 
an overall 48% reduction in total symptom 
scores, compared with a 30% reduction in the 
control group. Th e most common adverse ef-
fects were headache, rhinitis, and nonspecifi c 
pain.
Watch out for neuropathy with 
high doses of pyridoxine
A meta-analysis of pyridoxine in doses from 
50 to 600 mg per day for PMS included 9 RCTs. 
Relative to placebo, pyridoxine improved 
PMS symptom scores (odds ratio=2.32, 95% 
Long-term use 
of pyridoxine in 
doses >200 mg/d 
can cause 
neuropathy.
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EVIDENCE-BASED ANSWER
A chasteberry tree and calcium have demonstrated  effi  cacy and safety in treating symptoms of premen-
strual syndrome (PMS) (strength of recommendation [SOR]: 
A, randomized controlled trials [RCTs]). Pyridoxine and saf-
fron may be eff ective, but high doses of pyridoxine can cause 
neuropathy (SOR: B, RCT and meta-analysis of lower-quality 
studies).
Insuffi  cient evidence exists to recommend magnesium. 
St. John’s wort and evening primrose oil aren’t eff ective for 
managing PMS (SOR: B, inconsistent or limited quality pa-
tient-oriented evidence). No evidence was found to support 
black cohosh or vitamin E.
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confi dence interval, 1.95-2.54). Th e overall 
quality of studies was poor, however, with few 
subjects, widely varying doses, and diff erent 
outcome measurements.6
Two subsequent RCTs of 40 and 96 pa-
tients that weren’t included in the meta-
analysis failed to demonstrate reduced pre-
menstrual symptoms.7,8 Long-term use of 
pyridoxine in doses >200 mg/d can cause 
neuropathy.
Saffron shows promise in small study
A recent double-blind RCT evaluated the 
eff ect of 2 cycles of treatment with saff ron 
(Crocus sativus L), 30 mg twice daily, on PMS 
symptoms in 50 patients. Nineteen patients in 
the saff ron group showed a response, defi ned 
as 50% reduction in symptom severity, com-
pared with 2 patients in the placebo group 
(NNT=2). Th e study found no statistically 
signifi cant diff erence in frequency of adverse 
eff ects.9
Evidence for magnesium is sparse
Two RCTs comparing magnesium with pla-
cebo had low precision because of small num-
bers and short treatment duration.10,11 Th e 
fi rst (N=28) demonstrated reduced total Moos 
Menstrual Distress Questionnaire scores.10
Th e second study reported a decrease in fl uid 
retention symptoms by 2 points on an 80-point 
scale (P<.009) at 2 months, but no diff erence 
in total score.11
A further study, begun as an open trial 
of magnesium infusion for premenstrual 
dysphoric disorder (N=6), found a dramatic 
reduction in mood symptom scores. After 
converting to a randomized, blinded design 
(N=10), no diff erence was found compared 
with placebo.12
St. John’s wort, evening primrose oil 
don’t work
One randomized, double-blind controlled 
trial (N=125) of 600 mg St. John’s wort vs 
placebo over 2 cycles of treatment found 
no signifi cant changes in symptom score 
from baseline.13 Two double-blind cross-
over studies of 27 and 38 patients found that 
evening primrose oil had no eff ect on PMS 
symptoms.14,15
Recommendations
Th e Premenstrual Syndrome Guidelines of 
the American College of Obstetricians and 
Gynecologists (ACOG) state that calcium and 
magnesium have been shown to be eff ective 
in small trials and must be validated in larger 
trials before a strong evidence-based recom-
mendation can be made. ACOG’s guidelines 
also report minimal eff ectiveness with vita-
min B6 and vitamin E.16 
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